Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Presentation of an In Silico and In Vitro Exploration into Combining FDA-Approved Therapies for Treatment-Resistant Melanoma
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Poster
- By: CICALI, Brian (Stockton University, Galloway, United States)
- Co-author(s): Brian Cicali: Natural Sciences and Mathematics, Stockton University, Galloway, United States
Robert Olsen: Natural Sciences and Mathematics, Stockton University, Galloway, United States
BackgroundsMelanoma is the deadliest form of skin cancer, killing over 10,000 people annually in the United States. Although multiple FDA-approved therapies exist, treatment resistance is a major issue for oncologists.
AimsThis project utilizes in silico and in vitro experimentation to explore combination treatments of established melanoma.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019